MoonLake Immunotherapeutics Dossier - Source-backed chat

MoonLake Immunotherapeutics

MLTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.05

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $11.47Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $976.2M

Enterprise Value $597.8M

Shares Outstanding 73.8M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MoonLake Immunotherapeutics is a high-risk, high-reward clinical-stage biotechnology company focused on unlocking the potential of sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody. The investment thesis is highly event-driven and centered on the clinical and regulatory path of sonelokimab across multiple inflammatory indications, including hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). Following a positive Type B meeting with the FDA, the regulatory path for HS has been significantly de-risked, allowing a BLA submission in late 2026 without the need for additional clinical trials. With a robust cash runway extending into the second half of 2027 and multiple late-stage clinical readouts expected in 2026, MoonLake offers an attractive asymmetric payoff for risk-tolerant investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets13 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$28.54

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The FDA raises unexpected issues during the BLA review for HS, requiring additional clinical trials or delaying approval. Phase 3 readouts for psoriatic arthritis (IZAR program) fail to meet primary endpoints or show unfavorable safety signals. The resulting delays and clinical setbacks severely compress the company's cash runway, forcing highly dilutive equity financings and causing a steep decline in valuation.

Base CaseCentral scenario

The FDA accepts the BLA submission for sonelokimab in HS in late 2026, leading to potential approval and commercial launch in the US in the second half of 2027. Phase 3 trials in psoriatic arthritis (IZAR-1 and IZAR-2) deliver positive topline results, validating sonelokimab's efficacy in joint diseases and establishing it as a highly competitive, next-generation IL-17 inhibitor. The company maintains its cash runway through 2027, supported by its existing cash reserves and non-dilutive debt facilities.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

De-risked regulatory path for HS with FDA alignment on BLA submission using existing clinical data, avoiding the cost and time of new trials.
Sonelokimab's novel Nanobody technology offers structural advantages, including smaller size, enhanced tissue penetration, and dual inhibition of IL-17A and IL-17F.
Strong balance sheet with $357.9 million in cash and marketable securities as of March 31, 2026, providing a runway into the second half of 2027.
Multiple near-term late-stage clinical catalysts in 2026 across HS and PsA indications to drive valuation.

Key Investment Risks

Binary clinical and regulatory risk, as the company's valuation is entirely dependent on the success of a single asset (sonelokimab).
Pre-revenue status with ongoing substantial operating losses and cash burn from late-stage clinical development.
Highly competitive landscape in the IL-17 and immunology space, featuring established blockbusters and newly approved therapies.
No guarantee of FDA approval or successful commercial execution even if clinical trials are positive.

Thesis Invalidation Triggers

FDA refusal to file or complete rejection of the BLA submission for sonelokimab in hidradenitis suppurativa.
Failure of the Phase 3 IZAR-1 or IZAR-2 trials in psoriatic arthritis to meet their primary efficacy endpoints.
Emergence of serious, unexpected safety or tolerability signals in ongoing clinical trials.
Severe acceleration of cash burn that exhausts the cash runway significantly ahead of the projected late 2027 timeline.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.